Loading
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Previous close
$4.40
−$0.28 · -5.98%
Regular session · ET · Market data may be delayed.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Day range
Current $4.40
52-week range
Current $4.40
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
52
Mixed
Risk
55
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Day range
Current $4.40
52-week range
Current $4.40
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | 77K USD | — |
| Gross profit | — | — | — | −77K USD | — |
| Research and development | 24.77M USD | 40.49M USD | 54.87M USD | 29.51M USD | 16.91M USD |
| Selling, general, and administrative | 13.34M USD | 14.07M USD | 14.76M USD | 12.75M USD | 4.67M USD |
| Operating expenses | 38.11M USD | 54.55M USD | 69.64M USD | 42.19M USD | 21.57M USD |
| Interest income | 2.93M USD | 5.47M USD | 4.86M USD | 1.35M USD | 69K USD |
| Interest expense | — | — | — | 514K USD | — |
| Depreciation and amortization | — | 54.55M USD | 69.64M USD | 77K USD | — |
| Operating income | −38.11M USD | −54.55M USD | −69.64M USD | −42.26M USD | −21.57M USD |
| Net income | −35.17M USD | −51.32M USD | −64.73M USD | −40.96M USD | −21.54M USD |
Company facts updated Oct 12, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$9.00
104.55% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.73M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3.19M0.00%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2M0.00%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO839.22K0.00%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC394.37K0.03%1.32B USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM260K0.22%116.88M USD0.73%$15.9402+0.25%
Dimensional - US Small Cap ETFDFAS194.16K0.00%33.87B USD0.31%$78.35+0.32%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC191.54K0.02%1.04B USD0.20%$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMDimensional - US Small Cap ETFDFASGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
